As the COVID-19 situation evolves, Sol-Gel is committed to protecting the health, safety and welfare of our employees and their families. We have taken the following steps to help mitigate the spread of the coronavirus:
Business Continuity Plan (BCP) and Disaster Recovery Plan (DRP) were in place ahead of the COVID-19 crisis, and our Information Technology (IT) infrastructure allows recovery in case of a disaster including secured remote access to servers.
Purchase orders were placed to increase our current inventory.
Company is following all restrictions published by the Israeli Ministry of Health (IMOH).
SGT-210 Phase I proof-of-concept clinical study is ongoing subject to IMOH guidelines for COVID-19.
All employees returned to work at our facilities.
Company is taking all measures to ensure the well-being of our employees including frequent on-site cleaning and sanitary measures.
All business travel abroad was canceled and replaced with telecoms and video conferences.
EPSOLAY®️ (encapsulated benzoyl peroxide) & TWYNEO®️ (encapsulated benzoyl peroxide and encapsulated tretinoin)
Our CMOs (Contract Manufacturer Organizations) for Epsolay and Twyneo are open despite COVID-19.
We therefore do not anticipate delays in the submission of the NDAs or the production of the commercial/validation batches for both Epsolay and Twyneo.
This is of course, a dynamic situation which we will be monitoring closely.
Epsolay and Twyneo are registered trademarks of Sol-Gel Technologies Ltd.